Trials / Terminated
TerminatedNCT04377659
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later. |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2022-10-28
- Completion
- 2022-10-28
- First posted
- 2020-05-06
- Last updated
- 2025-05-28
- Results posted
- 2023-06-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04377659. Inclusion in this directory is not an endorsement.